medigraphic.com

2016, Number 2

<< Back Next >>

Rev Med MD 2016; 7.8 (2)

Obesity and kidney disease: hidden consequences of the epidemic

Kovesdy CP, Furth S, Zoccali C

Language: English
References: 88
Page: 39-45
PDF size: 7538.60 Kb.


Text Extraction

Obesity has become a worldwide epidemic, and its prevalence has been projected to grow by 40% in the next decade. This increasing prevalence has implications for the risk of diabetes, cardiovascular disease and also for Chronic Kidney Disease. A high body mass index is one of the strongest risk factors for new-onset Chronic Kidney Disease. In individuals affected by obesity, a compensatory hyperfiltration occurs to meet the heightened metabolic demands of the increased body weight. The increase in intraglomerular pressure can damage the kidneys and raise the risk of developing Chronic Kidney Disease in the long-term. The incidence of obesity-related glomerulopathy has increased ten-fold in recent years. Obesity has also been shown to be a risk factor for nephrolithiasis, and for a number of malignancies including kidney cancer. This year the World Kidney Day promotes education on the harmful consequences of obesity and its association with kidney disease, advocating healthy lifestyle and health policy measures that makes preventive behaviors an affordable option.


REFERENCES

  1. Forouzanfar MH, Alexander L, Anderson HR, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 386:2287-2323, 2015

  2. Flegal KM, Kruszon-Moran D, Carroll MD, et al.: Trends in Obesity Among Adults in the United States, 2005 to 2014. JAMA 315:2284-2291, 2016

  3. Cattaneo A, Monasta L, Stamatakis E, et al. Overweight and obesity in infants and pre-school children in the European Union: a review of existing data. Obes Rev 11:389-398, 2010

  4. Olaya B, Moneta MV, Pez O, Bitfoi A, et al. Countrylevel and individual correlates of overweight and obesity among primary school children: a crosssectional study in seven European countries. BMC Public Health 15:475, 2015

  5. Subramanian SV, Perkins JM, Ozaltin E, Davey SG: Weight of nations: a socioeconomic analysis of women in low- to middle-income countries. Am J Clin Nutr 93:413-421, 2011

  6. Tsujimoto T, Sairenchi T, Iso H, et al. The doseresponse relationship between body mass index and the risk of incident stage >/=3 chronic kidney disease in a general japanese population: the Ibaraki prefectural health study (IPHS). J Epidemiol 24:444- 451, 2014

  7. Elsayed EF, Sarnak MJ, Tighiouart H, et al. Waist-tohip ratio, body mass index, and subsequent kidney disease and death. Am J Kidney Dis 52:29-38, 2008

  8. Pinto-Sietsma SJ, Navis G, Janssen WM, de ZD, Gans RO, de Jong PE: A central body fat distribution is related to renal function impairment, even in lean subjects. Am J Kidney Dis 41:733-741, 2003

  9. Foster MC, Hwang SJ, Larson MG, et al. Overweight, obesity, and the development of stage 3 CKD: the Framingham Heart Study. Am J Kidney Dis 52:39-48, 2008

  10. Kramer H, Luke A, Bidani A, et al. Obesity and prevalent and incident CKD: the Hypertension Detection and Follow-Up Program. Am J Kidney Dis 46:587-594, 2005

  11. Chang A, Van HL, Jacobs DR, Jr., Liu K, et al. Lifestyle-related factors, obesity, and incident microalbuminuria: the CARDIA (Coronary Artery Risk Development in Young Adults) study. Am J Kidney Dis 62:267-275, 2013

  12. Ejerblad E, Fored CM, Lindblad P, et al. Obesity and risk for chronic renal failure. J Am Soc Nephrol 17:1695-1702, 2006

  13. Gelber RP, Kurth T, Kausz AT, et al. Association between body mass index and CKD in apparently healthy men. Am J Kidney Dis 46:871-880, 2005

  14. Lu JL, Molnar MZ, Naseer A, et al.Association of age and BMI with kidney function and mortality: a cohort study. Lancet Diabetes Endocrinol 3:704-714, 2015

  15. Munkhaugen J, Lydersen S, Wideroe TE, Hallan S: Prehypertension, obesity, and risk of kidney disease: 20-year follow-up of the HUNT I study in Norway. Am J Kidney Dis 54:638-646, 2009

  16. Iseki K, Ikemiya Y, Kinjo K, et al. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int 65:1870- 1876, 2004

  17. Vivante A, Golan E, Tzur D, et al. Body mass index in 1.2 million adolescents and risk for end-stage renal disease. Arch Intern Med 172:1644-1650, 2012

  18. Hsu C, McCulloch C, Iribarren C, et al. Body mass index and risk for end-stage renal disease. Ann Intern Med 144:21-28, 2006

  19. Lu JL, Kalantar-Zadeh K, Ma JZ, et al.Association of body mass index with outcomes in patients with CKD. J Am Soc Nephrol 25:2088-2096, 2014

  20. Thoenes M, Reil JC, Khan BV, et al. Abdominal obesity is associated with microalbuminuria and an elevated cardiovascular risk profile in patients with hypertension. Vasc Health Risk Manag 5:577-585, 2009

  21. Kramer H, Gutierrez OM, Judd SE, et al. Waist Circumference, Body Mass Index, and ESRD in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study. Am J Kidney Dis 67:62- 69, 2016

  22. Foster MC, Hwang SJ, Massaro JM, et al. Association of subcutaneous and visceral adiposity with albuminuria: the Framingham Heart Study. Obesity (Silver Spring) 19:1284-1289, 2011

  23. Postorino M, Marino C, Tripepi G, Zoccali C: Abdominal obesity and all-cause and cardiovascular mortality in end-stage renal disease. J Am Coll Cardiol 53:1265-1272, 2009

  24. Kovesdy CP, Czira ME, Rudas A, et al. Body mass index, waist circumference and mortality in kidney transplant recipients. Am J Transplant 10:2644-2651, 2010

  25. Scales CD, Jr., Smith AC, Hanley JM, Saigal CS: Prevalence of kidney stones in the United States. Eur Urol 62:160-165, 2012

  26. Curhan GC, Willett WC, Rimm EB, et al. Body size and risk of kidney stones. J Am Soc Nephrol 9:1645- 1652, 1998

  27. Taylor EN, Stampfer MJ, Curhan GC: Obesity, weight gain, and the risk of kidney stones. JAMA 293:455-462, 2005

  28. Bhaskaran K, Douglas I, Forbes H, et al. Bodymass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults. Lancet 384:755-765, 2014

  29. Arnold M, Pandeya N, Byrnes G, et al. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol 16:36-46, 2015

  30. Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371:569-578, 2008

  31. Bluher M: The distinction of metabolically 'healthy' from 'unhealthy' obese individuals. Curr Opin Lipidol 21:38-43, 2010

  32. Sharma K: The link between obesity and a l b u m i n u r i a : a d i p o n e c t i n a n d p o d o c y t e dysfunction. Kidney Int 76:145-148, 2009

  33. Wolf G, Ziyadeh FN: Leptin and renal fibrosis. Contrib Nephrol 151:175-183, 2006

  34. Ellington AA, Malik AR, Klee GG, et al. Association of plasma resistin with glomerular filtration rate and albuminuria in hypertensive adults. Hypertension 50:708-714, 2007

  35. Bastard JP, Maachi M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 17:4-12, 2006

  36. Furukawa S, Fujita T, Shimabukuro M, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114:1752-1761, 2004

  37. Ruan XZ, Varghese Z, Moorhead JF: An update on the lipid nephrotoxicity hypothesis. Nat Rev Nephrol 5:713-721, 2009

  38. Ruster C, Wolf G: The role of the reninangiotensin- aldosterone system in obesity-related renal diseases. Semin Nephrol 33:44-53, 2013

  39. Oterdoom LH, de Vries AP, Gansevoort RT, et al. Fasting insulin modifies the relation between age and renal function. Nephrol Dial Transplant 22:1587- 1592, 2007

  40. Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988

  41. Kambham N, Markowitz GS, Valeri AM, et al. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 59:1498-1509, 2001

  42. de Vries AP, Ruggenenti P, Ruan XZ, et al. Fatty kidney: emerging role of ectopic lipid in obesityrelated renal disease. Lancet Diabetes Endocrinol 2:417-426, 2014

  43. Foster MC, Hwang SJ, Porter SA, et al. Fatty kidney, hypertension, and chronic kidney disease: the Framingham Heart Study. Hypertension 58:784- 790, 2011

  44. Henegar JR, Bigler SA, Henegar LK, et al.Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol 12:1211-1217, 2001

  45. Knight SF, Quigley JE, Yuan J, et al. Endothelial dysfunction and the development of renal injury in spontaneously hypertensive rats fed a high-fat diet. Hypertension 51:352-359, 2008

  46. Tsuboi N, Utsunomiya Y, Kanzaki G, et al. Low glomerular density with glomerulomegaly in obesity-related glomerulopathy. Clin J Am Soc Nephrol 7:735-741, 2012

  47. Ribstein J, du CG, Mimran A: Combined renal effects of overweight and hypertension. Hypertension 26:610-615, 1995

  48. Maalouf NM, Sakhaee K, Parks JH, Coe FL, Adams-Huet B, Pak CY: Association of urinary pH with body weight in nephrolithiasis. Kidney Int 65:1422-1425, 2004

  49. Lemann J, Jr., Pleuss JA, Worcester EM, et al. Urinary oxalate excretion increases with body size and decreases with increasing dietary calcium intake among healthy adults. Kidney Int 49:200-208, 1996

  50. Siener R, Glatz S, Nicolay C, Hesse A: The role of overweight and obesity in calcium oxalate stone formation. Obes Res 12:106-113, 2004

  51. Taylor EN, Stampfer MJ, Curhan GC: Diabetes mellitus and the risk of nephrolithiasis. Kidney Int 68:1230-1235, 2005

  52. Klisic J, Hu MC, Nief V, et al. Insulin activates Na(+)/H(+) exchanger 3: biphasic response and glucocorticoid dependence. Am J Physiol Renal Physiol 283:F532-F539, 2002

  53. Chobanian MC, Hammerman MR: Insulin stimulates ammoniagenesis in canine renal proximal tubular segments. Am J Physiol 253:F1171- F1177, 1987

  54. Daudon M, Lacour B, Jungers P: Influence of body size on urinary stone composition in men and women. Urol Res 34:193-199, 2006

  55. Sinha MK, Collazo-Clavell ML, Rule A, et al.Hyperoxaluric nephrolithiasis is a complication of Roux-en-Y gastric bypass surgery. Kidney Int 72:100-107, 2007

  56. Calle EE, Kaaks R: Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4:579-591, 2004

  57. Dalamaga M, Diakopoulos KN, Mantzoros CS: The role of adiponectin in cancer: a review of current evidence. Endocr Rev 33:547-594, 2012

  58. Lamas O, Marti A, Martinez JA: Obesity and immunocompetence. Eur J Clin Nutr 56 Suppl 3:S42- S45, 2002

  59. Lim C, Savan R: The role of the IL-22/IL-22R1 axis in cancer. Cytokine Growth Factor Rev 25:257- 271, 2014

  60. Grivennikov SI, Greten FR, Karin M: Immunity, inflammation, and cancer. Cell 140:883-899, 2010

  61. Kovesdy CP, Anderson JE, Kalantar-Zadeh K: Paradoxical association between body mass index and mortality in men with CKD not yet on dialysis. Am J Kidney Dis 49:581-591, 2007

  62. Kalantar-Zadeh K, Kuwae N, Wu DY, et al. Associations of body fat and its changes over time with quality of life and prospective mortality in hemodialysis patients. Am J Clin Nutr 83:202-210, 2006

  63. Beddhu S, Pappas LM, Ramkumar N, et al. Effects of body size and body composition on survival in hemodialysis patients. J Am Soc Nephrol 14:2366- 2372, 2003

  64. Curtis JP, Selter JG, Wang Y, et al. The obesity paradox: body mass index and outcomes in patients with heart failure. Arch Intern Med 165:55-61, 2005

  65. Wilson DO, Rogers RM, Wright EC, Anthonisen NR: Body weight in chronic obstructive pulmonary disease. The National Institutes of Health Intermittent Positive-Pressure Breathing Trial. Am Rev Respir Dis 139:1435-1438, 1989

  66. Escalante A, Haas RW, del R, I: Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. Arch Intern Med 165:1624-1629, 2005

  67. Kalantar-Zadeh K, Kilpatrick RD, Kuwae N, Wu DY: Reverse epidemiology: a spurious hypothesis or a hardcore reality? Blood Purif 23:57-63, 2005

  68. Noori N, Kopple JD, Kovesdy CP, et al. Mid-arm muscle circumference and quality of life and survival in maintenance hemodialysis patients. Clin J Am Soc Nephrol 5:2258-2268, 2010

  69. Dekker FW, de MR, van Dijk PC, et al. Survival analysis: time-dependent effects and time-varying risk factors. Kidney Int 74:994-997, 2008

  70. Snyder JJ, Foley RN, Gilbertson DT, et al. Body size and outcomes on peritoneal dialysis in the United States. Kidney Int 64:1838-1844, 2003

  71. Lee PS, Sampath K, Karumanchi SA, et al. Plasma gelsolin and circulating actin correlate with hemodialysis mortality. J Am Soc Nephrol 20:1140- 1148, 2009

  72. Horwich TB, Fonarow GC, Hamilton MA, et al. The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol 38:789- 795, 2001

  73. Stenvinkel P, Marchlewska A, Pecoits-Filho R, et al. Adiponectin in renal disease: relationship to phenotype and genetic variation in the gene encoding adiponectin. Kidney Int 65:274-281, 2004

  74. Mohamed-Ali V, Goodrick S, Bulmer K, et al. Production of soluble tumor necrosis factor receptors by human subcutaneous adipose tissue in vivo. Am J Physiol 277:E971-E975, 1999

  75. Rauchhaus M, Coats AJ, Anker SD: The endotoxin-lipoprotein hypothesis. Lancet 356:930- 933, 2000

  76. Jandacek RJ, Anderson N, Liu M, et al. Effects of yo-yo diet, caloric restriction, and olestra on tissue distribution of hexachlorobenzene. Am J Physiol Gastrointest Liver Physiol 288:G292-G299, 2005

  77. Kramer HJ, Saranathan A, Luke A, et al. Increasing body mass index and obesity in the incident ESRD population. J Am Soc Nephrol 17:1453-1459, 2006

  78. Postorino M, Mancini E, D'Arrigo G, et al. Body mass index trend in haemodialysis patients: the shift of nutritional disorders in two Italian regions. Nephrol Dial Transplant 2016

  79. 2008-2013 Action Plan for the Global Strategy for the Prevention and Control of Noncommunicable Diseases. 2009. World Health Organization.

  80. O'Donoghue DJ, Stevens PE: A decade after the KDOQI CKD/guidelines: a perspective from the United Kingdom. Am J Kidney Dis 60:740-742, 2012

  81. Bolignano D, Zoccali C: Effects of weight loss on renal function in obese CKD patients: a systematic review. Nephrol Dial Transplant 28 Suppl 4:iv82-iv98, 2013

  82. Chang Y, Ryu S, Choi Y, et al. Metabolically Healthy Obesity and Development of Chronic Kidney Disease: A Cohort Study. Ann Intern Med 164:305-312, 2016

  83. Wing RR, Bolin P, Brancati FL, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 369:145-154, 2013

  84. Mallamaci F, Ruggenenti P, Perna A, et al. ACE inhibition is renoprotective among obese patients with proteinuria. J Am Soc Nephrol 22:1122-1128, 2011

  85. Friedman AN, Wolfe B: Is Bariatric Surgery an Effective Treatment for Type II Diabetic Kidney Disease? Clin J Am Soc Nephrol 11:528-535, 2016

  86. Chang AR, Chen Y, Still C, et al. Bariatric surgery is associated with improvement in kidney outcomes. Kidney Int 90:164-171, 2016

  87. Jamal MH, Corcelles R, Daigle CR, et al. Safety and effectiveness of bariatric surgery in dialysis patients and kidney transplantation candidates. Surg Obes Relat Dis 11:419-423, 2015

  88. Ahmadi SF, Zahmatkesh G, Ahmadi E, Set al. Association of Body Mass Index with Clinical Outcomes in Non-Dialysis-Dependent Chronic Kidney Disease: A Systematic Review and Meta- Analysis. Cardiorenal Med 6:37-49, 2015




2020     |     www.medigraphic.com